Valuation: Quest PharmaTech Inc.

Market Cap 3.38M 2.37M 2.12M 1.98M 1.8M 229M 3.41M 23.76M 9.28M 117M 8.9M 8.71M 375M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.06M 2.74M 2.55M 2.32M 296M 4.4M 30.68M 11.99M 151M 11.5M 11.25M 484M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 day-20.00%
1 week-20.00%
Current month-20.00%
3 months-20.00%
6 months-33.33%
Current year-42.86%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 2004-06-16
Director of Finance/CFO - 2004-12-31
Director TitleAgeSince
Director/Board Member - 2004-06-16
Chairman - 2021-07-04
Director/Board Member - 2021-07-04
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 OtherCompany 0 0% -
10/21/25 Other

Chief Executive Officer

1,000,000 0.5913%
10/21/25 Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
-20.00%-20.00%-42.86%-66.67% 2.37M
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.16%+2.68%+51.09% 58.7B
-2.39%+0.50%+3.41%+31.33% 48.36B
-8.95%-12.03%+278.76%+611.13% 43.05B
-1.85%-2.60%+26.59%+27.26% 42.48B
-5.92%-4.74%-2.66%+97.78% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.12%-4.58%-13.05%-15.46% 23.93B
-4.45%-10.57%-39.99%+296.21% 22.22B
Average -6.79%-2.37%+26.50%+117.10% 38.61B
Weighted average by Cap. -5.79%-1.88%+40.69%+130.50%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.26M -1.13M -1.05M -956K -122M -1.81M -12.65M -4.94M -62.13M -4.74M -4.64M -200M 5M 3.51M 3.13M 2.92M 2.65M 339M 5.04M 35.11M 13.72M 172M 13.16M 12.87M 554M
Net Debt 795K 557K 498K 465K 422K 53.92M 801K 5.58M 2.18M 27.42M 2.09M 2.05M 88.16M 986K 691K 618K 576K 523K 66.86M 993K 6.92M 2.7M 34M 2.59M 2.54M 109M
Projected Income Statement - Annual - Quest PharmaTech Inc.
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume